VRCA
Verrica Pharmaceuticals Inc
4.10$
-1.7%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | -50.3% | +3,787.4% | -99.2% | -45.6% | +391.9% | +1,502.7% | -31.8% | +92.5% | +35.3% | -134.4% | – | +899.7% | +269.4% | +12.9% | -64.5% | -1.4% | +16.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +18.1% | +80.2% | +39.0% | -21.2% | -24.2% | +1,761.4% | -97.8% | +100.0% | +6.6% | +14,084.1% | -94.5% | -52.4% | -19.7% | +43.7% | -32.3% | +16.8% | +124.5% | +26.3% | -36.5% | -1.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.8% | – | – | – | -103.3% | – | -137.1% | – | – | +5,926.1% | -770.2% | – | +72.4% | -147.8% | – | – | +304.8% | +8.4% | -72.1% | +12.0% | +20.6% | – | |
| – | -69.9% | +89.7% | +14.6% | -0.2% | -16.9% | +288.5% | -3.5% | +41.1% | -8.7% | -12.5% | -22.4% | +30.3% | +23.2% | -28.0% | +41.7% | -54.5% | +136.0% | -35.7% | +9.2% | -10.8% | -27.2% | +61.3% | -29.5% | +8.9% | -9.5% | +109.0% | +13.7% | -18.3% | -7.0% | -32.9% | -27.5% | -51.5% | +95.7% | -19.2% | +19.4% | +14.3% | +53.2% | +56.3% | – | |
| – | -97.1% | +114.5% | +101.7% | +32.8% | +212.0% | +153.9% | +47.1% | -11.1% | +8.2% | +1.5% | -2.8% | +15.0% | +24.1% | +2.4% | -9.0% | +110.0% | -32.6% | +10.7% | +9.9% | -36.1% | +0.1% | +1.1% | -24.1% | +262.2% | -69.6% | +37.5% | +237.8% | -15.3% | -12.7% | +3.9% | -2.8% | -58.7% | +38.3% | +3.6% | +6.2% | -9.1% | +16.9% | +3.6% | – | |
| – | -70.2% | +92.1% | +24.0% | +5.6% | +33.5% | +219.2% | +17.2% | +14.3% | -2.0% | -6.3% | -13.0% | +22.1% | +23.7% | -12.6% | +11.7% | +24.9% | -0.8% | -10.9% | +9.6% | -29.1% | -8.5% | +20.5% | -26.4% | -52.4% | +121.3% | +65.2% | +128.9% | -82.9% | +367.1% | -6.8% | -6.8% | -39.8% | +0.2% | -4.0% | +8.5% | -8.4% | +30.2% | +30.6% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -17,985.0% | – | – | – | – | – | -528.9% | – | – | – | – | – | – | – | – | – | – | +7.7% | -526.9% | – | – | – | |
| – | -100.0% | – | – | +0.0% | -100.0% | – | – | – | – | – | – | – | – | +310.9% | +1.5% | +8.0% | +3.7% | +4.8% | +1.4% | +0.5% | -1.4% | -1.5% | -92.4% | -29.6% | +777.2% | -100.0% | – | +39.1% | +0.6% | +2.1% | +0.3% | -1.1% | -6.2% | -3.3% | -1.7% | -37.2% | -87.8% | +2.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -7,247.0% | – | – | – | – | – | – | – | – | – | – | -234.3% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | -54.7% | -49.2% | +1,137.5% | -96.0% | +3.1% | -6.1% | +3,438.7% | -3.4% | -1.2% | -91.8% | -426.7% | – | – | -156.4% | – | +30.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -7,247.0% | – | – | – | – | – | – | – | – | – | – | -234.3% | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -6,769.2% | – | – | – | – | – | -1,296.1% | – | – | – | – | – | – | – | – | – | – | -20.9% | -427.8% | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.